AAAAAA

   
Results: 1-8 |
Results: 8
NADPH : cytochrome C (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
Authors: Saunders, MP Patterson, AV Chinje, EC Harris, AL Stratford, IJ
Citation: Mp. Saunders et al., NADPH : cytochrome C (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line, BR J CANC, 82(3), 2000, pp. 651-656
The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
Authors: Saunders, MP Jaffar, M Patterson, AV Nolan, J Naylor, MA Phillips, RM Harris, AL Stratford, IJ
Citation: Mp. Saunders et al., The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions, BIOCH PHARM, 59(8), 2000, pp. 993-996
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects
Authors: Propper, DJ Saunders, MP Salisbury, AJ Long, L O'Byrne, KJ Braybrooke, JP Dowsett, M Taylor, M Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects, CLIN CANC R, 5(7), 1999, pp. 1682-1689
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
Authors: Macaulay, VM O'Byrne, KJ Saunders, MP Braybrooke, JP Long, L Gleeson, F Mason, CS Harris, AL Brown, P Talbot, DC
Citation: Vm. Macaulay et al., Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions, CLIN CANC R, 5(3), 1999, pp. 513-520
A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma
Authors: O'Byrne, KJ Philip, PA Propper, DJ Braybrooke, JP Saunders, MP Bates, NP Taylor, MA Madigan, D Ganesan, TS Talbot, DC Harris, AL
Citation: Kj. O'Byrne et al., A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma, ANN ONCOL, 10(8), 1999, pp. 981-983
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Authors: Chinje, EC Patterson, AV Saunders, MP Lockyer, SD Harris, AL Stratford, IJ
Citation: Ec. Chinje et al., Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?, BR J CANC, 81(7), 1999, pp. 1127-1133
Enzymology of tirapazamine metabolism: a review
Authors: Patterson, AV Saunders, MP Chinje, EC Patterson, LH Stratford, IJ
Citation: Av. Patterson et al., Enzymology of tirapazamine metabolism: a review, ANTI-CAN DR, 13(6), 1998, pp. 541-573
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
Authors: O'Byrne, KJ Koukourakis, MI Saunders, MP Salisbury, AJ Isaacs, R Varcoe, S Taylor, M Ganesan, TS Harris, AL Talbot, DC
Citation: Kj. O'Byrne et al., Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer, BR J CANC, 77(11), 1998, pp. 1950-1956
Risultati: 1-8 |